NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

With respect to PFS, NWBO should have clarified the December 2016 slide from UCLA and whether it meant all placebo had already PFS progressed. That's an honest reading of the chart. Even fairer now that we know it was based upon shipping (and likely inventory) data.

Dr. Ashkan's plea, as a clinician, to move toward unblinding the trial should naw on the conscious of everyone at NWBO, the SAB and regulators -- particularly when he believes everyone benefits from DCVax-L -- just some more than others.

LP obviously believes DCVax-L is suited for frontline treatment.

What are we doing?